{
  "items": "50",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Chidozie Ugwumba Sells 5,582 Shares of Clene (NASDAQ:CLNN) Stock",
      "url": "https://www.marketbeat.com/instant-alerts/chidozie-ugwumba-sells-5582-shares-of-clene-nasdaqclnn-stock-2025-12-23/",
      "time_published": "20251223T221045",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Major shareholder Chidozie Ugwumba sold 5,582 shares of Clene (NASDAQ:CLNN) stock on Friday, December 19th, valued at $36,003.90. This sale is part of a larger series of transactions in December, totaling 136,298 shares and reducing his ownership by 1.42%. Despite the insider selling, analysts maintain a \"Moderate Buy\" rating with an average price target of $32.60 for Clene shares.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.939877"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.833918"
        },
        {
          "topic": "finance",
          "relevance_score": "0.724739"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.734971"
        }
      ],
      "overall_sentiment_score": -0.273446,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.299434",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 4,367 Shares of Stock",
      "url": "https://www.marketbeat.com/instant-alerts/clene-nasdaqclnn-major-shareholder-chidozie-ugwumba-sells-4367-shares-of-stock-2025-12-23/",
      "time_published": "20251223T221045",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Chidozie Ugwumba, a significant shareholder in Clene Inc. (NASDAQ:CLNN), recently sold 4,367 shares of the company's stock for $28,560.18, reducing his holdings by 1.13% to 383,201 shares. This sale is part of a pattern of insider selling throughout December, even as analysts maintain a \"Moderate Buy\" rating for the stock despite its current negative EPS and mixed financial sentiment. Clene Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle therapies for neurodegenerative disorders.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.927909"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.804785"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.737448"
        }
      ],
      "overall_sentiment_score": -0.400794,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.420056",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Have Insiders Sold Clene Shares Recently?",
      "url": "https://www.sahmcapital.com/news/content/have-insiders-sold-clene-shares-recently-2025-12-21",
      "time_published": "20251221T163400",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "An insider at Clene Inc. (NASDAQ:CLNN) recently sold US$1.7m worth of shares, reducing their holding by 40%. While this was a substantial sale, it occurred above the current share price. The article notes that insider ownership is relatively low at 14% and there have been no insider purchases in the last year, leading to a cautious outlook on the stock.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.949555"
        }
      ],
      "overall_sentiment_score": -0.349665,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.327568",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Have Insiders Sold Clene Shares Recently?",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-clnn/clene/news/have-insiders-sold-clene-shares-recently/amp",
      "time_published": "20251221T140941",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "An insider at Clene Inc. recently sold US$1.7m worth of stock, reducing their total holding by 40%. While this was a significant sale, it occurred at a price well above the current market value. Insiders own 14% of Clene shares, and there have been no insider purchases in the last year, which may not inspire confidence in the stock.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.917745"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.720345"
        }
      ],
      "overall_sentiment_score": -0.281176,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.267663",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Clene (NASDAQ: CLNN) 10% owner discloses December stock sales",
      "url": "https://www.stocktitan.net/sec-filings/CLNN/form-4-clene-inc-insider-trading-activity-1290505a4c3c.html",
      "time_published": "20251219T030910",
      "authors": [
        "NULL"
      ],
      "summary": "A 10% owner of Clene Inc. (NASDAQ: CLNN), Chidozie Ugwumba, disclosed a series of open-market stock sales of common stock in December 2025 through Symbiosis II, LLC. The transactions, coded \"S\" on a Form 4 SEC filing, occurred between December 3 and December 18, 2025, with share prices ranging from $5.70 to $7.86. Following these sales, the beneficial ownership of Clene common stock by Symbiosis II, LLC stands at 393,150 shares as of December 18, 2025.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.920558"
        },
        {
          "topic": "finance",
          "relevance_score": "0.838473"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.720032"
        }
      ],
      "overall_sentiment_score": -0.370118,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.398258",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Owner Ugwumba Sells 257,795 ($1.7M) Of Clene Inc [CLNN]",
      "url": "https://www.tradingview.com/news/reuters.com,2025-12-18:newsml_WSAwQ9P9a:0-owner-ugwumba-sells-257-795-1-7m-of-clene-inc-clnn/",
      "time_published": "20251219T030910",
      "authors": [
        "Refinitiv"
      ],
      "summary": "Ugwumba Chidozie, a beneficial owner of Clene Inc (CLNN), filed a Form 4 disclosing the sale of 257,795 shares of the company's stock between December 3 and December 18, 2025, at an average price of $6.69 per share, totaling over $1.7 million. After the transaction, Ugwumba's indirect holdings in Clene Inc stand at 393,150 shares. This information is provided by The Washington Service, specializing in insider trading analysis.",
      "banner_image": "NULL",
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.907218"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.749335"
        }
      ],
      "overall_sentiment_score": 0.00701,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.328339",
          "ticker_sentiment_score": "0.026103",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Chidozie Ugwumba Sells 7,030 Shares of Clene (NASDAQ:CLNN) Stock",
      "url": "https://www.marketbeat.com/instant-alerts/chidozie-ugwumba-sells-7030-shares-of-clene-nasdaqclnn-stock-2025-12-18/",
      "time_published": "20251219T030906",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Chidozie Ugwumba, a major shareholder in Clene Inc. (NASDAQ:CLNN), sold 7,030 shares of the company's stock on December 16th, which was part of a larger series of trades between December 4th and 18th, totaling approximately 201,218 shares. Following these transactions, Ugwumba holds 401,850 shares valued at about $2.54 million. The insider selling coincided with a 7.4% drop in CLNN shares to $6.04, amidst mixed analyst ratings and the company reporting a quarterly EPS loss.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936854"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.810487"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.702433"
        },
        {
          "topic": "finance",
          "relevance_score": "0.609305"
        }
      ],
      "overall_sentiment_score": -0.407405,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.396894",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 15,031 Shares of Stock",
      "url": "https://www.marketbeat.com/instant-alerts/insider-selling-clene-nasdaqclnn-major-shareholder-sells-15031-shares-of-stock-2025-12-18/",
      "time_published": "20251219T020951",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 15,031 shares of the company's stock on December 9th for $5.95 per share, part of a larger divestment of approximately 201,218 shares totaling $1.28 million in December. Following these transactions, Ugwumba's stake in Clene decreased by 3.25%. Clene's shares fell 7.4% to $6.04 amidst these insider sales, with the company remaining loss-making and analysts holding a \"Moderate Buy\" consensus with an average target price of $32.60.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936446"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.811485"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.928411"
        }
      ],
      "overall_sentiment_score": -0.31668,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.301285",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 72,748 Shares of Stock",
      "url": "https://www.marketbeat.com/instant-alerts/insider-selling-clene-nasdaqclnn-major-shareholder-sells-72748-shares-of-stock-2025-12-18/",
      "time_published": "20251219T020941",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Chidozie Ugwumba, a major shareholder in Clene (NASDAQ:CLNN), sold 72,748 shares of the company's stock on December 4th for $489,594.04, reducing his stake by 12.24%. These sales were part of a series of transactions from December 5th to December 18th. Despite Clene missing its Q3 earnings estimates, analysts generally maintain a \"Moderate Buy\" rating with an average target price of $32.60.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923212"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.802440"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.710142"
        }
      ],
      "overall_sentiment_score": 0.019154,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.344548",
          "ticker_sentiment_score": "0.031280",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Chidozie Ugwumba Sells 56,577 Shares of Clene (NASDAQ:CLNN) Stock",
      "url": "https://www.marketbeat.com/instant-alerts/chidozie-ugwumba-sells-56577-shares-of-clene-nasdaqclnn-stock-2025-12-18/",
      "time_published": "20251219T000906",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Chidozie Ugwumba, a major shareholder in Clene Inc. (NASDAQ:CLNN), sold 56,577 shares on December 3rd at an average price of $7.86, totaling approximately $444,695. This initial sale, detailed in an SEC filing, reduced his stake to 594,368 shares. He continued selling throughout December, offloading roughly 185,047 shares in total, including this initial transaction.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.925637"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.818444"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.916639"
        }
      ],
      "overall_sentiment_score": -0.42925,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.387500",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Clene (NASDAQ:CLNN) Major Shareholder Sells $68,664.20 in Stock",
      "url": "https://www.marketbeat.com/instant-alerts/clene-nasdaqclnn-major-shareholder-sells-6866420-in-stock-2025-12-18/",
      "time_published": "20251218T230906",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Chidozie Ugwumba, a major shareholder in Clene Inc. (NASDAQ:CLNN), sold 10,580 shares of the company's stock for $68,664.20 on December 15th, reducing his stake to 408,880 shares. This transaction is part of a series of sales by Ugwumba throughout early to mid-December, totaling approximately $1.28 million. Clene's stock currently trades at $6.04, with analysts maintaining a \"Moderate Buy\" rating and an average price target of $32.60 despite recent negative earnings.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.910995"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.823460"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.701987"
        }
      ],
      "overall_sentiment_score": -0.205958,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.218191",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Chidozie Ugwumba Sells 21,463 Shares of Clene (NASDAQ:CLNN) Stock",
      "url": "https://www.marketbeat.com/instant-alerts/chidozie-ugwumba-sells-21463-shares-of-clene-nasdaqclnn-stock-2025-12-18/",
      "time_published": "20251218T030906",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Chidozie Ugwumba, a major shareholder in Clene Inc. (NASDAQ:CLNN), sold 21,463 shares of the company's stock on December 8th, bringing his direct ownership to 462,922 shares. This transaction was part of several share sales throughout December, resulting in a 4.43% reduction of his position. Following the news, Clene's stock traded down 7.4% to $6.04, with the company reporting a financial miss in its most recent earnings.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.920059"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.832134"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.705291"
        }
      ],
      "overall_sentiment_score": -0.204105,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.200402",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "EBIT per share of Clene Inc \u2013 FWB:84C0",
      "url": "https://www.tradingview.com/symbols/FWB-84C0/financials-statistics-and-ratios/ebit-per-share/",
      "time_published": "20251216T030910",
      "authors": [
        "NULL"
      ],
      "summary": "This article provides a financial overview of Clene Inc (FWB:84C0) on the Frankfurt Stock Exchange, focusing on its EBIT per share data. It outlines the company's financial information and market data sources, noting that the market is currently closed.",
      "banner_image": "https://s3-symbol-logo.tradingview.com/clene--big.svg",
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.933484"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.733468"
        },
        {
          "topic": "finance",
          "relevance_score": "0.613896"
        }
      ],
      "overall_sentiment_score": 0.014003,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.000032",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene to Present at the Emerging Growth Conference",
      "url": "https://www.manilatimes.net/2025/12/09/tmt-newswire/globenewswire/clene-to-present-at-the-emerging-growth-conference/2239905",
      "time_published": "20251209T140915",
      "authors": [
        "GlobeNewswire"
      ],
      "summary": "Clene Inc. (Nasdaq: CLNN) and its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company focused on neurodegenerative diseases, will present at the Emerging Growth Conference on December 10, 2025, at 4:25 p.m. ET. The virtual presentation will provide a corporate update, with a webcast available on Clene's website and a replay accessible afterward. The conference serves as a platform for public companies to communicate updates to the investment community.",
      "banner_image": "NULL",
      "source": "The Manila Times",
      "category_within_source": "General",
      "source_domain": "The Manila Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.902985"
        },
        {
          "topic": "finance",
          "relevance_score": "0.629674"
        }
      ],
      "overall_sentiment_score": 0.297388,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.297548",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Clene (Nasdaq: CLNN) reports NfL, GFAP drops in ALS as it targets 2026 accelerated NDA",
      "url": "https://www.stocktitan.net/news/CLNN/clene-announces-statistically-significant-als-biomarker-results-8mhbj4mxnx1v.html",
      "time_published": "20251208T040927",
      "authors": [
        "NULL"
      ],
      "summary": "Clene Inc. announced statistically significant reductions in NfL and GFAP biomarkers in ALS patients treated with CNM-Au8, correlating with improved survival. The company plans a Q1 2026 accelerated approval NDA submission to the FDA, following a planned Type C meeting to present their comprehensive data. Despite these positive results, the stock experienced a significant negative market reaction, declining 22.03% on the news due to existing financial concerns and financing overhang.",
      "banner_image": "https://ml.globenewswire.com/media/YTY4YzkxMTUtY2YwMy00M2U4LTgzYmMtMTIyYmQzZWRhOGM4LTEyNTc5OTktMjAyNS0xMi0wMy1lbg==/tiny/Clene-Inc-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928200"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.703815"
        }
      ],
      "overall_sentiment_score": -0.15837,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.128531",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene to Provide CNM-Au8\u00ae ALS Program Update",
      "url": "https://investingnews.com/clene-to-provide-cnm-au8-r-als-program-update/",
      "time_published": "20251207T020951",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. announced plans to provide an update on its CNM-Au8 program for Amyotrophic Lateral Sclerosis (ALS) and will host an investor call and webcast on Wednesday, December 3, 2025, at 8:30 AM ET. The webcast will feature presentations from Clene's CEO and President, Head of Medical, Chief Development Officer, and a Key Opinion Leader. CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health and function by improving mitochondrial health and protecting neuronal function.",
      "banner_image": "https://investingnews.com/media-library/image.png?id=32377065&width=1200&height=288",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.829712"
        }
      ],
      "overall_sentiment_score": 0.327547,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.348656",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Benchmark reiterates Buy rating on Clene stock amid positive biomarker data",
      "url": "https://www.investing.com/news/analyst-ratings/benchmark-reiterates-buy-rating-on-clene-stock-amid-positive-biomarker-data-93CH-4391295",
      "time_published": "20251205T060938",
      "authors": [
        "Investing.com"
      ],
      "summary": "Benchmark has reiterated its Buy rating and $31.00 price target for Clene (NASDAQ:CLNN) due to positive biomarker data analysis for its CNM-Au8 treatment, which shows statistically significant reductions in neurofilament light and glial fibrillary acidic protein. This data suggests potential for accelerated FDA approval, with Clene planning a Q1 2026 meeting with the FDA and aiming to start its Phase 3 RESTORE-ALS trial in H1 2026. The company is also advancing its therapeutic pipeline with positive clinical data for Multiple Sclerosis and new preclinical data for Parkinson's Disease.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923500"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.818505"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.634675"
        }
      ],
      "overall_sentiment_score": 0.711435,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.700904",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Clene Inc. (NASDAQ:CLNN) Receives Average Rating of \"Moderate Buy\" from Analysts",
      "url": "https://www.marketbeat.com/instant-alerts/clene-inc-nasdaqclnn-receives-average-rating-of-moderate-buy-from-analysts-2025-12-04/",
      "time_published": "20251205T035224",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Clene Inc. (NASDAQ:CLNN) has an average \"Moderate Buy\" rating from analysts, with a consensus 12-month price target of $32.60, indicating substantial upside potential. The company recently missed earnings expectations, reporting EPS of ($0.85) versus ($0.60) predicted, and revenue of $0.02M against $0.06M expected. Currently, the stock is trading down about 22%, with a market capitalization of $74.6 million.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.910988"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.819329"
        }
      ],
      "overall_sentiment_score": -0.290722,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.279734",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Clene Updates on CNM-Au8\u00ae ALS Program",
      "url": "https://www.tipranks.com/news/company-announcements/clene-updates-on-cnm-au8-als-program",
      "time_published": "20251204T035224",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Clene Inc. hosted a webcast on December 3, 2025, to provide an update on its CNM-Au8\u00ae program for amyotrophic lateral sclerosis (ALS). This update could influence Clene's market positioning and stakeholder interests. Analysts currently rate CLNN as a Hold with a $9.50 price target, while TipRanks' AI Analyst, Spark, assigns a Neutral rating due to poor financial performance despite positive technical momentum.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Defensive-8-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930952"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.803556"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.735725"
        }
      ],
      "overall_sentiment_score": 0.038622,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.341701",
          "ticker_sentiment_score": "0.000680",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene Inc Announces Significant ALS Biomarker Results",
      "url": "https://www.tradingview.com/news/tradingview:2601e2127ad97:0-clene-inc-announces-significant-als-biomarker-results/",
      "time_published": "20251204T035224",
      "authors": [
        "NULL"
      ],
      "summary": "Clene Inc. announced significant ALS biomarker results supporting accelerated approval for CNM-Au8, showing substantial reductions in NfL and GFAP which are linked to improved survival. The company plans a Type C meeting in Q1 2026 for NDA submission and held an investor webcast on December 3, 2025, to discuss these findings.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905936"
        }
      ],
      "overall_sentiment_score": 0.472944,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.494552",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8",
      "url": "https://investingnews.com/clene-announces-statistically-significant-als-biomarker-results-supporting-accelerated-approval-pathway-for-cnm-au8-r/",
      "time_published": "20251203T035224",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Nanomedicine, Inc. announced statistically significant reductions in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in ALS patients treated with CNM-Au8, supporting an accelerated approval pathway. These biomarker improvements are strongly linked to longer survival, bolstering the potential for CNM-Au8 as a disease-modifying therapy for Amyotrophic Lateral Sclerosis. The company plans to present these analyses to the FDA in Q1 2026 and expects to file an NDA for accelerated approval.",
      "banner_image": "https://investingnews.com/media-library/image.png?id=32377065&width=1200&height=288",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948940"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.646734"
        }
      ],
      "overall_sentiment_score": 0.843095,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.840132",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Clene (Nasdaq: CLNN) to host Dec. 3 CNM-Au8 ALS program update webcast at 8:30 a.m. ET",
      "url": "https://www.stocktitan.net/news/CLNN/clene-to-provide-cnm-au8-als-program-3ptq9jyhxoes.html",
      "time_published": "20251203T035224",
      "authors": [
        "NULL"
      ],
      "summary": "Clene Inc. (Nasdaq: CLNN) will host an investor call and webcast on December 3, 2025, at 8:30 a.m. ET to provide an update on its CNM-Au8 program for amyotrophic lateral sclerosis (ALS). The webcast will feature key company executives and a key opinion leader, accessible via a provided link or the company's investor relations website. An archived version will be available after the live event.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.815593"
        }
      ],
      "overall_sentiment_score": 0.147356,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.118024",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene Inc. to Provide Update on CNM-Au8 Program in ALS during Investor Call on December 3, 2025",
      "url": "https://www.quiverquant.com/news/Clene+Inc.+to+Provide+Update+on+CNM-Au8+Program+in+ALS+during+Investor+Call+on+December+3%2C+2025",
      "time_published": "20251202T195224",
      "authors": [
        "NULL"
      ],
      "summary": "Clene Inc. announced an investor call and webcast scheduled for December 3, 2025, to provide an update on its CNM-Au8 program for amyotrophic lateral sclerosis (ALS). The event will feature presentations from CEO Rob Etherington and other key executives, focusing on the investigational therapy's role in treating neurodegenerative diseases by improving mitochondrial function and reducing oxidative stress. The company aims to communicate its progress and engagement with stakeholders regarding its first-in-class therapy.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.938073"
        }
      ],
      "overall_sentiment_score": 0.141565,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.138881",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Institutions own 17% of Clene Inc. (NASDAQ:CLNN) shares but individual investors control 56% of the company",
      "url": "https://finance.yahoo.com/news/institutions-own-17-clene-inc-104142275.html",
      "time_published": "20251202T060938",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Individual investors hold a significant 56% ownership in Clene Inc. (NASDAQ:CLNN), giving them considerable influence over management and business strategy, while institutions own 17%. The top 25 shareholders collectively control less than half of the company's shares, indicating a widely disseminated ownership structure. Insiders, including the board of directors, own a reasonable proportion of the company, signaling their investment in the business.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/HkW.of1x4JHpvrHVFxKcTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwODtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2021-03/7d6207c0-7d34-11eb-bbee-858baefb8682",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.904621"
        },
        {
          "topic": "finance",
          "relevance_score": "0.704353"
        }
      ],
      "overall_sentiment_score": 0.130293,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.105759",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene Inc. (NASDAQ:CLNN): When Will It Breakeven?",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-clnn/clene/news/clene-inc-nasdaqclnn-when-will-it-breakeven",
      "time_published": "20251202T060938",
      "authors": [
        "Simply Wall St or NULL"
      ],
      "summary": "Clene Inc. (NASDAQ:CLNN) is projected to reach breakeven around 2027, according to seven industry analysts. The clinical-stage pharmaceutical company, with a current market cap of US$107m, is expected to reduce its losses and generate positive profits within two years, driven by an anticipated annual growth rate of 78%. Investors are looking closely at how the company's novel clean-surfaced nanotechnology therapeutics will contribute to this profitability target.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936334"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.803589"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.709827"
        },
        {
          "topic": "technology",
          "relevance_score": "0.605004"
        }
      ],
      "overall_sentiment_score": 0.414668,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.431137",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Clene Inc. (NASDAQ:CLNN): When Will It Breakeven?",
      "url": "https://www.sahmcapital.com/news/content/clene-inc-nasdaqclnn-when-will-it-breakeven-2025-11-29",
      "time_published": "20251201T035224",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Clene Inc. (NASDAQ:CLNN), a clinical-stage pharmaceutical company with a US$107m market-cap, is expected to reach profitability by 2027, according to analysts. The company is predicted to incur a final loss in 2026 before generating positive profits of US$2.2m in 2027, requiring an average annual growth rate of 78% to breakeven. Investors should also note the company currently has negative equity on its balance sheet.",
      "banner_image": "https://images.simplywall.st/asset/chart/339429732-earnings-per-share-growth-1-dark-2/1764422376824",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.908189"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.835475"
        },
        {
          "topic": "finance",
          "relevance_score": "0.721398"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.623398"
        }
      ],
      "overall_sentiment_score": 0.233418,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.230206",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference",
      "url": "https://investingnews.com/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference/",
      "time_published": "20251120T050927",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company, announced its participation in the Benchmark 14th Annual Discovery One-on-One Investor Conference. Management will host 1x1 investor meetings at the conference, scheduled for December 4, 2025, in New York City. Clene focuses on treating neurodegenerative diseases like ALS and MS by improving mitochondrial health and neuronal function.",
      "banner_image": "https://investingnews.com/media-library/image.png?id=32377065&width=1200&height=288",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.935200"
        },
        {
          "topic": "finance",
          "relevance_score": "0.746870"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.745951"
        }
      ],
      "overall_sentiment_score": 0.322255,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.341189",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights",
      "url": "https://investingnews.com/clene-reports-third-quarter-2025-financial-results-and-recent-operating-highlights/",
      "time_published": "20251113T050913",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. announced its third-quarter 2025 financial results and provided updates on its CNM-Au8 programs for neurodegenerative diseases. The company is nearing completion of ALS biomarker data analyses and plans to submit a New Drug Application in Q1 2026, aiming for accelerated approval. Clene also reported $7.9 million in cash and cash equivalents as of September 30, 2025, extending its cash runway into Q2 2026.",
      "banner_image": "https://investingnews.com/media-library/image.png?id=32377065&width=1200&height=288",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.923130"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.938884"
        },
        {
          "topic": "finance",
          "relevance_score": "0.601124"
        }
      ],
      "overall_sentiment_score": 0.415383,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.437743",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Clene to Present at the Emerging Growth Conference",
      "url": "https://investingnews.com/clene-to-present-at-the-emerging-growth-conference/",
      "time_published": "20251020T020907",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. announced that its management will present at the Emerging Growth Conference on October 23, 2025, at 3:10 p.m. ET, providing a corporate update. A webcast of the presentation will be available on the \"Events\" section of Clene's website and via a registration link. Clene is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, including ALS and MS, and is developing CNM-Au8\u00ae.",
      "banner_image": "https://investingnews.com/media-library/image.png?id=32377065&width=1200&height=288",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944372"
        }
      ],
      "overall_sentiment_score": 0.210628,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.212974",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Clene Inc. (NASDAQ:CLNN) Receives $32.60 Consensus Price Target from Analysts - Defense World",
      "url": "https://www.defenseworld.net/2025/10/18/clene-inc-nasdaqclnn-receives-32-60-consensus-price-target-from-analysts.html",
      "time_published": "20251018T052034",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "Clene Inc. (NASDAQ:CLNN) has received a consensus price target of $32.60 from analysts. Several firms have recently updated their price objectives and ratings for Clene, with institutional investors also adjusting their holdings in the company. Clene is a clinical-stage pharmaceutical company focusing on novel clean-surfaced nanotechnology therapeutics, with its lead drug candidate CNM-Au8 undergoing various clinical trials for conditions like ALS and Parkinson's Disease.",
      "banner_image": "https://www.marketbeat.com/logos/clene-inc-logo-1200x675.png?v=20240611113742",
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.810491"
        }
      ],
      "overall_sentiment_score": 0.037431,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.344445",
          "ticker_sentiment_score": "0.025933",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene Enters Equity Distribution Agreement with Canaccord - TipRanks",
      "url": "https://www.tipranks.com/news/company-announcements/clene-enters-equity-distribution-agreement-with-canaccord",
      "time_published": "20251017T210432",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Clene Inc. has entered into an equity distribution agreement with Canaccord Genuity LLC to sell up to $25 million in common stock. The biotechnology company has already filed to offer an additional $18.88 million in shares by October 2025, following previous sales of approximately $6.12 million. Despite strong technical indicators, Clene's financial instability, reflected in revenue, profitability, and cash flow challenges, impacts its overall stock score.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Defensive-5-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.926354"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.822049"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.719728"
        },
        {
          "topic": "finance",
          "relevance_score": "0.609657"
        }
      ],
      "overall_sentiment_score": 0.025096,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.345139",
          "ticker_sentiment_score": "0.031814",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene to Participate in a Panel Discussion at the Maxim Growth Summit - Investing News Network",
      "url": "https://investingnews.com/clene-to-participate-in-a-panel-discussion-at-the-maxim-growth-summit/",
      "time_published": "20251016T043402",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. announced that its management will participate in a neurodegenerative diseases panel discussion and host investor meetings at the Maxim Growth Summit on October 22, 2025, in New York City. The clinical-stage biopharmaceutical company focuses on treating neurodegenerative diseases like ALS and MS by improving mitochondrial health and protecting neuronal function. Clene will also be available for one-on-one investor meetings.",
      "banner_image": "https://investingnews.com/media-library/image.png?id=32377065&width=1200&height=288",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915845"
        },
        {
          "topic": "finance",
          "relevance_score": "0.606485"
        }
      ],
      "overall_sentiment_score": 0.039267,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.307239",
          "ticker_sentiment_score": "0.032194",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene to Participate in a Panel Discussion at the Maxim Growth Summit - MarketScreener",
      "url": "https://www.marketscreener.com/news/clene-to-participate-in-a-panel-discussion-at-the-maxim-growth-summit-ce7d5adfd98df027",
      "time_published": "20251015T123138",
      "authors": [],
      "summary": "Clene Inc. (Nasdaq: CLNN) announced its participation in a panel discussion at the Maxim Growth Summit and will host 1x1 investor meetings on October 22, 2025, in New York City. The panel will focus on \"Neurodegenerative Diseases \u2013 Under the Radar Innovators in One of the Most Challenging Therapeutic Categories.\" Clene, a clinical-stage biopharmaceutical company, is focused on improving mitochondrial health and protecting neuronal function for neurodegenerative diseases like ALS and MS.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.706618"
        }
      ],
      "overall_sentiment_score": 0.024667,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.312246",
          "ticker_sentiment_score": "0.019365",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oct 22, 2025 \u2014 Clene at Maxim Growth Summit: Neurodegenerative Panel in NYC, 1x1 Investor Meetings - Stock Titan",
      "url": "https://www.stocktitan.net/news/CLNN/clene-to-participate-in-a-panel-discussion-at-the-maxim-growth-6hrt1mgsr95t.html",
      "time_published": "20251015T123000",
      "authors": [],
      "summary": "Clene (Nasdaq: CLNN) announced its management will participate in a Neurodegenerative Diseases Panel and host 1x1 investor meetings at the Maxim Growth Summit in New York City on October 22, 2025. The company and its subsidiary, Clene Nanomedicine Inc., focus on mitochondrial health and neuronal protection for diseases such as ALS and MS, with their investigational therapy CNM-Au8\u00ae. Investors can request individual sessions through a Maxim representative.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.522637"
        },
        {
          "topic": "finance",
          "relevance_score": "0.423565"
        }
      ],
      "overall_sentiment_score": 0.009857,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.308385",
          "ticker_sentiment_score": "0.013484",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nanotechnology Stocks To Research \u2013 October 12th",
      "url": "https://www.defenseworld.net/2025/10/14/nanotechnology-stocks-to-research-october-12th.html",
      "time_published": "20251014T083157",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "This article highlights five nanotechnology stocks to watch: Onto Innovation (ONTO), Nano Dimension (NNDM), NVE (NVEC), and Clene (CLNN). It provides a brief description of each company's operations and their focus within the nanotechnology sector, from process control tools and additive manufacturing to spintronics and clinical-stage therapeutics. These companies were chosen based on recent high dollar trading volume in the nanotechnology stock sector.",
      "banner_image": "https://www.marketbeat.com/logos/onto-innovation-inc-logo-1200x675.png?v=20221117095052",
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "technology",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.817521"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.706474"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.612047"
        }
      ],
      "overall_sentiment_score": 0.011399,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.349986",
          "ticker_sentiment_score": "0.047044",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene stock maintains Buy rating at Benchmark on positive MS data",
      "url": "https://www.investing.com/news/analyst-ratings/clene-stock-maintains-buy-rating-at-benchmark-on-positive-ms-data-93CH-4257798",
      "time_published": "20250926T093700",
      "authors": [
        "Investing.com"
      ],
      "summary": "Clene Inc. (NASDAQ:CLNN) has maintained its Buy rating and a $31.00 price target at Benchmark following positive clinical data for its CNM-Au8 treatment for Multiple Sclerosis. The data showed improved brain energy metabolism, a significant finding for Clene's development pipeline. Despite recent adjustments to price targets by Benchmark and Canaccord Genuity due to funding concerns and Q2 2025 results, the Buy rating remains consistent across multiple firms, with H.C. Wainwright also reiterating a Buy rating based on positive Parkinson's Disease data.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906617"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.819574"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.736448"
        }
      ],
      "overall_sentiment_score": 0.037063,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.341221",
          "ticker_sentiment_score": "0.010185",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8\u00ae Improves Brain Energy Metabolism in Multiple Sclerosis Patients",
      "url": "https://investingnews.com/clene-presents-new-clinical-data-at-ectrims-2025-meeting-demonstrating-cnm-au8-r-improves-brain-energy-metabolism-in-multiple-sclerosis-patients/",
      "time_published": "20250925T000000",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. presented new clinical data at ECTRIMS 2025 demonstrating that its drug CNM-Au8\u00ae significantly improves brain energy metabolism, specifically the NAD+/NADH ratio, in patients with multiple sclerosis and Parkinson's disease. The REPAIR studies show a correlation between bioenergetic failure and disease severity, and CNM-Au8 treatment was found to restore these deficits. The FDA has also expressed openness to considering broader treatment effects beyond the Expanded Disability Status Scale for MS clinical trials.",
      "banner_image": null,
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.455811,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.482913",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Clene Inc. Advances Toward NDA Submission for ALS Therapy CNM-Au8\u00ae",
      "url": "https://www.citybuzz.co/2025/09/09/clene-inc-advances-toward-nda-submission-for-als-therapy-cnm-au8/",
      "time_published": "20250909T000000",
      "authors": [],
      "summary": "Clene Inc. is moving closer to submitting a New Drug Application (NDA) for its ALS therapy, CNM-Au8\u00ae, with an expected submission in Q4 2025. The company recently released Q2 2025 financial results and highlighted progress in its clinical programs focused on neurodegenerative diseases. CEO Rob Etherington emphasized upcoming meetings with the FDA regarding survival data and biomarker analyses, marking the final steps towards potential accelerated approval for ALS.",
      "banner_image": null,
      "source": "citybuzz -",
      "category_within_source": "General",
      "source_domain": "citybuzz -",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.926427"
        }
      ],
      "overall_sentiment_score": 0.467312,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.488599",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Neurodegenerative Disease Biotech Clene to Showcase ALS and MS Pipeline at Major Investment Conference",
      "url": "https://www.stocktitan.net/news/CLNN/clene-to-present-at-the-h-c-wainwright-27th-annual-global-investment-3ftnhhac3ql7.html",
      "time_published": "20250902T080000",
      "authors": [],
      "summary": "Clene Inc. (NASDAQ:CLNN), a biopharmaceutical company focusing on neurodegenerative diseases, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The company will deliver a virtual presentation on September 5, 2025, and host one-on-one investor meetings, highlighting its pipeline for ALS and multiple sclerosis. Investors can access the presentation via Clene's website.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.746402"
        }
      ],
      "overall_sentiment_score": 0.19147,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.162303",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Clene (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission, Extends Runway into 2026",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/BMWYY/pressreleases/34333917/clene-nasdaq-clnn-reports-q2-2025-results-as-company-prepares-for-nda-submission-extends-runway-into-2026/",
      "time_published": "20250822T103500",
      "authors": [
        "Investor Brand Network"
      ],
      "summary": "Clene Inc. reported its Q2 2025 financial results, including $7.3 million in cash and cash equivalents, which extends its cash runway into Q1 2026. The company is preparing to submit a New Drug Application (NDA) for its lead candidate CNM-Au8 in ALS by year-end 2025, with FDA meetings scheduled for Q3 2025 to discuss survival benefit data and MS development plans. Analysis of neurofilament light biomarker data from an NIH-sponsored EAP program is anticipated in early Q4 2025.",
      "banner_image": null,
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.908888"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.849787"
        }
      ],
      "overall_sentiment_score": 0.49986,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.477089",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Clene Inc. Announces Q2 2025 Financial Results and Plans for FDA Meetings on CNM-Au8\u00ae Development in ALS and MS",
      "url": "https://www.quiverquant.com/news/Clene+Inc.+Announces+Q2+2025+Financial+Results+and+Plans+for+FDA+Meetings+on+CNM-Au8%C2%AE+Development+in+ALS+and+MS",
      "time_published": "20250814T125100",
      "authors": [],
      "summary": "Clene Inc. announced its Q2 2025 financial results, highlighting ongoing progress with its CNM-Au8 programs for ALS and MS, and plans for upcoming FDA meetings. The company is preparing for an NDA submission for accelerated approval of CNM-Au8 in ALS by the end of 2025 and an end-of-Phase 2 meeting for MS. Despite a net loss of $7.4 million, Clene reported a cash runway into Q1 2026.",
      "banner_image": null,
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.920428"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.832680"
        },
        {
          "topic": "finance",
          "relevance_score": "0.615754"
        }
      ],
      "overall_sentiment_score": 0.12657,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.115170",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates",
      "url": "https://finance.yahoo.com/news/clene-inc-clnn-reports-q2-131501284.html",
      "time_published": "20250814T020907",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Clene Inc. (CLNN) reported a Q2 loss of $0.78 per share, missing the Zacks Consensus Estimate of a $0.49 loss, though it was an improvement from a $1.06 loss a year ago. The company also missed revenue estimates, posting $0.03 million for the quarter against an expectation of higher figures. Clene shares have underperformed the market year-to-date, and its earnings outlook, currently a Zacks Rank #3 (Hold), suggests it will perform in line with the market in the near future.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.929855"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.730981"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.601338"
        }
      ],
      "overall_sentiment_score": -0.40524,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.430408",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Clene Inc. to discuss ALS drug with FDA by November end",
      "url": "https://ca.investing.com/news/company-news/clene-inc-to-discuss-als-drug-with-fda-by-november-end-93CH-3602429",
      "time_published": "20240916T090000",
      "authors": [
        "Investing.com"
      ],
      "summary": "Clene Inc. plans to meet with the FDA by the end of November 2024 to re-evaluate the accelerated approval pathway for its ALS drug candidate, CNM-Au8, following initial feedback. The company will present additional data on biomarkers, clinical endpoints, and survival, building on over 700 patient-years of safety data. Investors are closely monitoring the meeting's outcome and the company's financial health, as analysts have revised earnings upwards despite anticipated unprofitability for the current year.",
      "banner_image": null,
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.843209"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.726586"
        }
      ],
      "overall_sentiment_score": 0.334932,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.329148",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8\u00ae in ALS (ACT-EAP)",
      "url": "https://www.stocktitan.net/news/CLNN/clene-provides-update-on-its-nih-funded-expanded-access-program-for-q03japo0sa6v.html",
      "time_published": "20240528T073000",
      "authors": [],
      "summary": "Clene Inc. has provided updates on its NIH-funded Expanded Access Program (ACT-EAP) for CNM-Au8 in ALS, announcing an 80% increase in enrollment capacity to 180 participants and the first patient visit planned for early June 2024. The program, a collaboration with Columbia University and Synapticure, aims to collect \"real-world\" data on the drug's efficacy, safety, survival, and disease progression without increasing the budget. This initiative is supported by a four-year NIH grant, validating the company's strategic direction and enhancing the understanding of ALS.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.455064,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.460081",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington",
      "url": "https://finance.yahoo.com/news/ibn-announces-lab-launch-podcast-123000323.html",
      "time_published": "20240501T123000",
      "authors": [],
      "summary": "IBN announced that Clene Inc. CEO Rob Etherington appeared on the \"From Lab to Launch\" podcast to discuss the company's work in addressing neurodegenerative diseases. Etherington highlighted Clene's pioneering catalytic nanotherapeutics, specifically CNM-Au8, designed to improve mitochondrial function and reduce reactive oxygen species for treating conditions like ALS and Parkinson's. He emphasized that these nanotherapeutics approach neurodegenerative disease treatment differently from traditional small molecule chemistry or biologics, leveraging physics and material science at the nanoscale to deliver energy to neurons.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.493499,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.490585",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Trials to watch: Four ALS drugs to keep an eye on",
      "url": "https://www.clinicaltrialsarena.com/features/trials-to-watch-als-drugs/",
      "time_published": "20240430T000000",
      "authors": [
        "Abigail Beaney"
      ],
      "summary": "This article highlights four promising drug candidates in mid-to-late-stage clinical trials for Amyotrophic Lateral Sclerosis (ALS), offering hope despite a recent setback from Amylyx Pharmaceuticals. Experts note a healthy pipeline with diverse mechanisms of action, expecting significant evolution in the ALS treatment landscape within the next decade. The featured drugs include candidates from Calico/AbbVie, AL-S Pharma, RAPA Therapeutics, and Clene, each with unique approaches to addressing ALS pathology.",
      "banner_image": null,
      "source": "Clinical Trials Arena",
      "category_within_source": "General",
      "source_domain": "Clinical Trials Arena",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.017312,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "0.336094",
          "ticker_sentiment_score": "0.028725",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland",
      "url": "https://investingnews.com/clene-announces-10-8-million-registered-direct-offering-and-5-million-debt-facility-from-the-state-of-maryland/",
      "time_published": "20221031T162618",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. (Nasdaq: CLNN) announced an approximately $10.8 million registered direct offering to existing stockholders, including affiliates of its board of directors. Concurrently, Clene secured a $5 million debt facility from the Maryland Department of Housing and Community Development, conditional on matching equity capital, which the direct offering will satisfy. These funds will support the clinical development of its lead drug candidate, CNM-Au8, for neurodegenerative diseases, particularly ALS, and provide capital into Q3 2023.",
      "banner_image": null,
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938581"
        },
        {
          "topic": "finance",
          "relevance_score": "0.811457"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.707569"
        }
      ],
      "overall_sentiment_score": 0.443173,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.427691",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3",
      "url": "https://investingnews.com/clene-to-report-healey-als-platform-trial-topline-results-on-monday-october-3/",
      "time_published": "20220930T162618",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. announced it will report topline results from the CNM-Au8\u00ae regimen of the HEALEY ALS Platform Trial on Monday, October 3rd. Management will host a conference call and webcast to discuss these results. CNM-Au8\u00ae is Clene's lead asset in clinical development for treating multiple sclerosis and amyotrophic lateral sclerosis.",
      "banner_image": null,
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.25879,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.254719",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Clene to Host VISIONARY-MS Results Call and Webcast on August 15",
      "url": "https://investingnews.com/clene-to-host-visionary-ms-results-call-and-webcast-on-august-15/",
      "time_published": "20220812T162618",
      "authors": [
        "Investing News Network"
      ],
      "summary": "Clene Inc. announced it will present results from its Phase 2 VISIONARY-MS trial on Monday, August 15, 2022, at 7:30 a.m. EDT. The company, which focuses on neurodegenerative disease treatment, will host a conference call and webcast for investors and media regarding these results. A replay of the webcast will be available on the Clene website after the event.",
      "banner_image": null,
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.842626"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.732600"
        }
      ],
      "overall_sentiment_score": 0.292176,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.257828",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "New Clene CFO to focus on financing runway amid beaten down sector, rising rates",
      "url": "https://www.cfodive.com/news/new-clene-cfo-to-focus-on-financing-runway-amid-beaten-down-sector-rising/618834/",
      "time_published": "20220214T162618",
      "authors": [
        "Maura Webber Sadovi"
      ],
      "summary": "Clene Nanomedicine's new CFO Morgan Brown plans to explore various financing options, including a shelf registration, fresh debt, or licensing agreements, to extend the biopharma company's financial runway in a challenging market. The company, which is developing treatments for neurodegenerative diseases like ALS, aims to secure capital to continue operations beyond 2022, despite its shares trading near a 52-week low. Brown believes successful clinical trial data will eventually boost the stock price and make an equity offering a viable financing option.",
      "banner_image": null,
      "source": "CFO Dive",
      "category_within_source": "General",
      "source_domain": "CFO Dive",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.810821"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.938716"
        }
      ],
      "overall_sentiment_score": 0.274222,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLNN",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.271068",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    }
  ]
}